Highlights of This Issue 6107

SPECIAL FEATURES

CCR Translations
6109  High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?  John F. de Groot  See article p. 6192

CCR New Strategies
6112  New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice  Jonathan W. Friedberg

Molecular Pathways
6118  The Two Faces of Interferon-γ in Cancer  M. Raza Zaidi and Glenn Merlino
6125  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer’s Inflammatory Roots  Hasan Korkaya, Suling Liu, and Max S. Wicha

Review
6130  Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis  Christopher Lieu, John Heymach, Michael Overman, Hai Tran, and Scott Kopetz

HUMAN CANCER BIOLOGY

CANCER THERAPY: PRECLINICAL

6151  Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models  Benjamin D. Hedley, Jenny E. Chu, D. George Ormond, Michel S. Beausoleil, Alexandra Boasie, Alison L. Allan, and Anargyros Xenocostas

6163  Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm  Alice Agliano, Ines Martin-Padura, Paola Marighetti, Giuliana Gregato, Angelica Calleri, Celia Prior, Miriam Redrado, Alfonso Calvo, and Francesco Bertolini


6192  Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells  Louisa von Baumgarten, David Brucker, Anca Turnicaru, Yvonne Kienast, Stefan Grau, Steffen Burgold, Jochen Herms, and Frank Winkler  See commentary p. 6109

6206  Enhancement of Carboplatin-Mediated Lung Cancer Cell Killing by Simultaneous Disruption of Glutathione and Thioredoxin Metabolism  Melissa A. Fath, Iman M. Ahmad, Carmen J. Smith, Jacquelyn Spence, and Douglas R. Spitz
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Liqun Chen, Benjamin A. Mooso, Maitreyee K. Jathal, Anisha Madhav, Sherra D. Johnson, Elyse van Spyk, Margarita Mikhailova, Alexandra Zierenberg-Ripoll, Lingru Xue, Ruth L. Vinall, Ralph W. de Vere White, and Paramita M. Ghosh

Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation
Zhen-Bin Ding, Bo Hui, Ying-Hong Shi, Jian Zhou, Yuan-Fei Peng, Cheng-Yu Gu, Hua Yang, Guo-Ming Shi, Ai-Wu Ke, Xiao-Ying Wang, Kang Song, Zhi Dai, Ying-Hao Shen, and Jia Fan

Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles
Francesc Balaguer, Leticia Moreira, Juan Jose Lozano, Alexander Link, Georgina Ramirez, Yan Shen, Miriam Cuatrecasas, Mildred Arnold, Stephen J. Meltzer, Sapna Syngal, Elena Stoffel, Rodrigo Jover, Xavier Llor, Antoni Castells, C. Richard Boland, Meritxell Gironella, and Ajay Goel

Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
Inna Serganova, Asif Rizwan, Xiaohui Ni, Sunitha B. Thakur, Jelena Vider, James Russell, Ronald Blasberg, and Jason A. Koutcher

Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination

Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer
Ryohei Nishino, Atsushi Takano, Hideko Osbina, Nobuhiro Ishikawa, Hirohiko Akiyama, Hiroyuki Ito, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, and Yataro Daigo

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst, John P. Riley, Mark E. Dudley, and Steven A. Rosenberg

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, and Gregory J. Riely

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, Ludmila Pruđkin, Jordi Andreu, Edith Rodríguez-Braun, Amparo Domingo, Jorge Guijarro, Cristina Gamez, Jordi Rodon, Serena Di Cosimo, Holly Brown, Jason Clark, James S. Hardwick, Robert A. Beckman, William D. Hanley, Karl Hsu, Emilio Calvo, Susana Roselló, Ronald B. Langdon, and José Baselga

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrs Cervantes, Jose Antonio Lopez-Martin, Jaime Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett Hall, Zhilong Yuan, Roland Knoblauch, and Sen Hong Zhuang

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, and Vincent A. Miller
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, Alain Morel, Valérie Gouilleux-Gruart, Celine Vignault-Desvignes, Hervé Watier, Erick Gamelin, and Gilles Paintaud

A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
Patricia R. Blank, Holger Moch, Thomas D. Szucs, and Matthias Schwenkglenks

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

ABOUT THE COVER
Growth of experimental glioma imaged in real time by in vivo multiphoton microscopy. This allows the study of the characteristic pattern of glioma growth and angiogenesis, and morphologic and functional vascular changes in response to antiangiogenic treatment. The cover image shows an U87 glioma expressing RFP (red) and tumor vessels (green, FITC dextran) 30 days after brain implantation (tumor diameter 3 mm). The image represents a maximum intensity projection of the mouse brain up to a depth of 350 µm. For details, see the article by von Baumgarten and colleagues on page 6192 of this issue.
Clinical Cancer Research

17 (19)

Clin Cancer Res 2011;17:6107-6366.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/17/19

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.